Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation

Autor: A. W. Dekker, C M P W Mandigers, John M. M. Raemaekers, Leo F. Verdonck, Jules P.P. Meijerink, A.V.M.B. Schattenberg
Přispěvatelé: Pediatrics
Rok vydání: 2003
Předmět:
Male
Follicular lymphoma
Graft vs Host Disease
Polymerase Chain Reaction
Gastroenterology
Antibodies
Monoclonal
Murine-Derived
Immunophenotyping
Recurrence
immune system diseases
hemic and lymphatic diseases
Antineoplastic Combined Chemotherapy Protocols
Etoposide
Hematology
Lymphoma
Non-Hodgkin
Graft vs Tumor Effect
Remission Induction
Antibodies
Monoclonal
Middle Aged
Combined Modality Therapy
Tissue Donors
Treatment Outcome
Vincristine
Lymphocyte Transfusion
Female
Rituximab
medicine.drug
Adult
medicine.medical_specialty
Prednisolone
Lymphocyte Depletion
Donor lymphocyte infusion
Internal medicine
medicine
Humans
Transplantation
Homologous
Mechlorethamine
Cyclophosphamide
Salvage Therapy
Peripheral Blood Stem Cell Transplantation
Transplantation
business.industry
Immunotherapy
gene therapy and transplantation [UMCN 1.4]
medicine.disease
Lymphoma
Methotrexate
Doxorubicin
Procarbazine
Immunology
Prednisone
Radiotherapy
Adjuvant
business
Progressive disease
Zdroj: Bone Marrow Transplantation, 32, 1159-63
Bone Marrow Transplantation, 32, 1159-1163. Nature Publishing Group
Bone Marrow Transplantation, 32, 12, pp. 1159-63
ISSN: 0268-3369
DOI: 10.1038/sj.bmt.1704290
Popis: Item does not contain fulltext Donor lymphocyte infusions (DLI) are used to treat relapsed haematological diseases after allogeneic stem cell transplantation (SCT). We treated seven patients with DLI for indolent non-Hodgkin's lymphoma relapsed after SCT. In available blood and bone marrow samples, lymphoma cells were analysed by real-time quantitative polymerase chain reaction of t(14;18)-positive cells in follicular lymphoma, and by immunophenotyping in small lymphocytic lymphoma. Before DLI, three patients were treated with chemo- and/or radiotherapy, and one with rituximab. Evaluable responses to pre-DLI therapy were stable disease in one and partial remission (PR) in two patients. Six patients responded to DLI (complete remission (CR) in four and PR in two). After DLI, acute graft-versus-host disease (GVHD) occurred in 3/6 patients, classified as grade 2, whereas only limited chronic GVHD was seen (n=5). The four continuous CR are lasting for median 65+ (43-89) months. In the remaining patient, not responding to DLI, progressive disease was seen later on; chemotherapy followed by another DLI resulted in CR. In three cases, clinical responses to DLI could be substantiated by molecular or immunophenotypic analysis of lymphoma cells. We conclude that DLI is effective for treatment of indolent lymphoma relapsing after SCT.
Databáze: OpenAIRE
Externí odkaz: